<DOC>
	<DOCNO>NCT02115542</DOCNO>
	<brief_summary>The main purpose study see regorafenib help control decrease cancer size patient cancer bile duct . Researchers also want find regorafenib safe tolerable .</brief_summary>
	<brief_title>Single Agent Regorafenib Refractory Advanced Biliary Cancers</brief_title>
	<detailed_description />
	<mesh_term>Bile Duct Neoplasms</mesh_term>
	<criteria>Histologically cytologically document carcinoma primary intra extrahepatic biliary system gall bladder clinical and/or radiologic evidence unresectable , locally advanced metastatic disease . Patients ampullary carcinoma eligible . Have fail 2 prior line systemic chemotherapy advance biliary cancer . Patients receive adjuvant chemotherapy evidence disease recurrence within 6 month completion adjuvant treatment also eligible . If patient receive adjuvant treatment disease recurrence 6 month , eligible fail one line systemic chemotherapy use treat disease recurrence . Eastern Cooperative Oncology Group ( ECOG ) Performance Status Assessment 0 1 Measurable nonmeasurable disease allow . Must treat vascular endothelial growth factor ( VEGF ) inhibitor . Prior 5Fluorouracil ( 5FU ) capecitabine treatment allow give radiosensitizer concurrently radiation therapy least 12 week prior registration give part adjuvant therapy regimen &gt; 6 month prior study enrollment . Life expectancy least 12 week ( 3 month ) For patient receive prior cryotherapy , radiofrequency ablation , therasphere , ethanol injection , transarterial chemoembolization ( TACE ) photodynamic therapy , follow criterion must meet : 28 day elapse since therapy ( lesion treat local therapy must present measureable . Able understand willing sign write informed consent form All acute toxic effect prior treatment resolve National Cancer Institute Common Terminology Criteria Adverse Events ( NCICTCAE ) v4.0 Grade 1 less time signing Informed Consent Form ( ICF ) . Adequate bone marrow liver function Participants receive 5FU capecitabine . Women childbearing potential must negative serum pregnancy test perform within 7 day prior start study drug . Men woman childbearing potential must agree use adequate contraception begin sign ICF least 3 month last dose study drug . Able swallow retain oral medication Previous assignment treatment study . Participants permanently withdraw study participation allow reenter study . Other investigational treatment within 21 day start study treatment Child Pugh B C Uncontrolled hypertension ( systolic pressure &gt; 140 mm Hg diastolic pressure &gt; 90 mm Hg [ NCICTCAE v4.0 ] repeat measurement ) despite optimal medical management Active clinically significant cardiac disease Evidence history bleed diathesis coagulopathy Any hemorrhage bleeding event ≥ NCI CTCAE Grade 3 within 4 week prior start study medication Participants thrombotic , embolic , venous , arterial event , cerebrovascular accident ( include transient ischemic attack ) deep vein thrombosis pulmonary embolism within 6 month inform consent Active malignancy except nonmelanoma skin cancer situ cervical cancer . Potential participant survive cancer curatively treat without evidence disease 3 year trial allow . All cancer treatment must complete least 3 year prior study entry ( i.e. , signature date inform consent form ) . Potential participant phaeochromocytoma Potential participant severe hepatic impairment ( ChildPugh Class C ) Known history human immunodeficiency virus ( HIV ) infection current chronic active hepatitis B C infection require treatment antiviral therapy . Ongoing infection &gt; Grade 2 NCICTCAE v4.0 Symptomatic metastatic brain meningeal tumor Presence nonhealing wound , nonhealing ulcer , bone fracture Renal failure require hemoor peritoneal dialysis Patients seizure disorder require medication Persistent proteinuria &gt; /= Grade 3 NCICTCAE v4.0 ( &gt; 3.5 g/24 hour , measure urine protein : creatinine ratio random urine sample ) Interstitial lung disease ongoing sign symptoms time informed consent Pleural effusion ascites cause respiratory compromise ( ≥ NCICTCAE version 4.0 Grade 2 dyspnea ) History organ allograft ( include corneal transplant ) Known suspect allergy hypersensitivity study drug , study drug class , excipients formulation give course trial Any malabsorption condition Women pregnant breastfeed Any condition , investigator 's opinion , make potential participant unsuitable trial participation Substance abuse , medical , psychological social condition may interfere participation study evaluation study result</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>biliary</keyword>
	<keyword>liver</keyword>
	<keyword>Refractory Advanced Biliary Cancers</keyword>
	<keyword>gallbladder cancer</keyword>
	<keyword>carcinoma</keyword>
	<keyword>intra-hepatic biliary system</keyword>
	<keyword>extra-hepatic biliary system</keyword>
	<keyword>gall bladder</keyword>
	<keyword>unresectable</keyword>
	<keyword>locally advanced</keyword>
	<keyword>metastatic disease</keyword>
	<keyword>Bile Duct Diseases</keyword>
	<keyword>Gallbladder Diseases</keyword>
	<keyword>regorafenib</keyword>
	<keyword>stivarga</keyword>
	<keyword>Bay 73-4506</keyword>
	<keyword>multikinase inhibitor</keyword>
</DOC>